344 related articles for article (PubMed ID: 32457353)
1. T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Roessner PM; Seiffert M
Leukemia; 2020 Aug; 34(8):2012-2024. PubMed ID: 32457353
[TBL] [Abstract][Full Text] [Related]
2. Expanded antigen-experienced CD160
Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
[TBL] [Abstract][Full Text] [Related]
3. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
Front Immunol; 2020; 11():612244. PubMed ID: 33552073
[TBL] [Abstract][Full Text] [Related]
4. CD4+ T Cells are Exhausted and Show Functional Defects in Chronic Lymphocytic Leukemia.
Allahmoradi E; Taghiloo S; Tehrani M; Hossein-Nattaj H; Janbabaei G; Shekarriz R; Asgarian-Omran H
Iran J Immunol; 2017 Dec; 14(4):257-269. PubMed ID: 29276179
[TBL] [Abstract][Full Text] [Related]
5. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
6. Control of chronic lymphocytic leukemia development by clonally-expanded CD8
Hanna BS; Roessner PM; Yazdanparast H; Colomer D; Campo E; Kugler S; Yosifov D; Stilgenbauer S; Schmidt M; Gabriel R; Lichter P; Seiffert M
Leukemia; 2019 Mar; 33(3):625-637. PubMed ID: 30267008
[TBL] [Abstract][Full Text] [Related]
7. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.
Riches JC; Davies JK; McClanahan F; Fatah R; Iqbal S; Agrawal S; Ramsay AG; Gribben JG
Blood; 2013 Feb; 121(9):1612-21. PubMed ID: 23247726
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
9. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8
Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H
Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227
[TBL] [Abstract][Full Text] [Related]
10. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia.
Scrivener S; Goddard RV; Kaminski ER; Prentice AG
Leuk Lymphoma; 2003 Mar; 44(3):383-9. PubMed ID: 12688308
[TBL] [Abstract][Full Text] [Related]
11. Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.
Hanna BS; Öztürk S; Seiffert M
Mol Immunol; 2019 Jun; 110():77-87. PubMed ID: 29173971
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.
Giordano Attianese GM; Marin V; Hoyos V; Savoldo B; Pizzitola I; Tettamanti S; Agostoni V; Parma M; Ponzoni M; Bertilaccio MT; Ghia P; Biondi A; Dotti G; Biagi E
Blood; 2011 May; 117(18):4736-45. PubMed ID: 21406718
[TBL] [Abstract][Full Text] [Related]
13. Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia.
Mackus WJ; Frakking FN; Grummels A; Gamadia LE; De Bree GJ; Hamann D; Van Lier RA; Van Oers MH
Blood; 2003 Aug; 102(3):1057-63. PubMed ID: 12689926
[TBL] [Abstract][Full Text] [Related]
14. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease.
Tötterman TH; Carlsson M; Simonsson B; Bengtsson M; Nilsson K
Blood; 1989 Aug; 74(2):786-92. PubMed ID: 2787679
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-10 receptor signaling promotes the maintenance of a PD-1
Hanna BS; Llaó-Cid L; Iskar M; Roessner PM; Klett LC; Wong JKL; Paul Y; Ioannou N; Öztürk S; Mack N; Kalter V; Colomer D; Campo E; Bloehdorn J; Stilgenbauer S; Dietrich S; Schmidt M; Gabriel R; Rippe K; Feuerer M; Ramsay AG; Lichter P; Zapatka M; Seiffert M
Immunity; 2021 Dec; 54(12):2825-2841.e10. PubMed ID: 34879221
[TBL] [Abstract][Full Text] [Related]
17. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
[TBL] [Abstract][Full Text] [Related]
18. Immunobiology of chronic lymphocytic leukemia.
Freedman AS
Hematol Oncol Clin North Am; 1990 Apr; 4(2):405-29. PubMed ID: 2182599
[TBL] [Abstract][Full Text] [Related]
19. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE
Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib treatment improves T cell number and function in CLL patients.
Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
